O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNαWilliam J. Sandborn, Paul Rutgeerts, Marion Blank et al.|Inflammatory Bowel Diseases|2016Cited by 48